Patient Demographics
| Demographic | PYP+ (n = 22) | PYP− (n = 42) | Total (n = 64) | P |
|---|---|---|---|---|
| Age | 81.0 (8.4) | 72.0 (13.8) | 75.1 (12.9) | 0.002* |
| Sex, male | 22 (100.0%) | 35 (83.3%) | 57 (89.1%) | 0.09† |
| Body mass index | 27.0 (3.5) | 27.2 (5.3) | 27.1 (4.8) | 0.89* |
| Systolic blood pressure (mm Hg) | 119.8 (16.4) | 136.6 (27.5) | 130.6 (25.3) | 0.029† |
| Diastolic blood pressure (mm Hg) | 73.7 (11.93) | 80.5 (15.73) | 78.1 (14.74) | 0.070† |
| Hypertension | 12 (63.2%) | 25 (73.5%) | 37 (69.8%) | 0.536† |
| History of coronary artery disease | 6 (31.6%) | 10 (29.4%) | 16 (30.2%) | 1.000† |
| History of diabetes mellitus | 2 (10.5%) | 10 (29.4%) | 12 (22.6%) | 0.174† |
| β-blocker | 10 (52.6%) | 22 (64.7%) | 32 (60.4%) | 0.559† |
| Calcium channel blocker | 1 (5.3%) | 9 (26.5%) | 10 (18.9%) | 0.076† |
| Angiotensin-converting-enzyme inhibitor | 3 (15.8%) | 5 (14.7%) | 8 (15.1%) | 1.000† |
| Angiotensin receptor blocker | 5 (26.3%) | 5 (14.7%) | 10 (18.9%) | 0.465† |
| Spironolactone | 4 (21.1%) | 5 (14.7%) | 9 (17.0%) | 0.706† |
| Amiodarone | 0 (0.0%) | 1 (2.9%) | 1 (1.9%) | 1.000† |
| Creatine | 1.3 (1.1–1.5) | 1.3 (1.1–1.8) | 1.3 (1.1–1.7) | 0.44‡ |
| N-terminal prohormone B-type natriuretic protein | 3,095.0 (1,640.0–7,323.0) | 3,097.0 (1,238.5–8,832.5) | 3,097.0 (1,407.0–7,447.0) | 0.99‡ |
| Low voltage on electrocardiography | 6 (28.6%) | 5 (11.9%) | 11 (17.5%) | 0.1575† |
| LV septal wall thickness (mm) | 18.3 (2.96) | 14.1 (3.43) | 15.7 (3.83) | 0.0001* |
| LV posterior wall thickness (mm) | 16.4 (2.63) | 13.1 (2.99) | 14.3 (3.28) | 0.0004* |
| LV mass (g) | 352.3 (108.5) | 272.4 (101.5) | 300.7 (110.1) | 0.005* |
| LV mass index (g/m2) | 175.7 (51.8) | 137.2 (42.5) | 150.4 (49.1) | 0.002* |
| LV End-diastolic diameter (mm) | 44.5 (6.69) | 47.2 (6.95) | 46.2 (6.91) | 0.143* |
| Ejection fraction (%) | 47.9 (15.2) | 51.8 (15.2) | 50.5 (15.2) | 0.34* |
| Stroke volume (mL) | 65.6 (25.7) | 76.4 (25.1) | 72.5 (25.6) | 0.1146‡ |
| Cardiac index (L/m2/min) | 2.4 (0.83) | 2.8 (0.88) | 2.6 (0.88) | 0.075† |
| Tricuspid annular plane systolic excursion by M-mode (mm) | 12.3 (3.30) | 17.2 (5.36) | 15.8 (5.29) | 0.0250‡ |
| Pericardial effusion | 8 (36.4%) | 6 (14.3%) | 14 (21.9%) | 0.0584† |
| Heart-to-contralateral ratio | 1.7 (0.4) | 1.1 (0.2) | 1.3 (0.4) | <0.001† |
| PYP scale¶ | 0 (0.0%) | 30 (71.4%) | 30 (46.9%) | <0.001† |
| 0 | 2 (9.1%) | 7 (16.7%) | 9 (14.1%) | |
| 1 | 6 (27.3%) | 2 (4.8%) | 8 (12.5%) | |
| 2 | 14 (63.6%) | 3 (7.1%) | 17 (26.6%) | |
| 3 | 0 (0.0%) | 30 (71.4%) | 30 (46.9%) |
* Unequal-variance 2-sample t test.
↵†Fisher exact test.
↵‡Wilcoxon rank-sum test.
↵¶Qualitative value for interpretation is determined by comparing uptake in myocardium. Grade 0 = no myocardial uptake, grade 1 = myocardial uptake less than bone uptake, grade 2 = myocardial uptake equal to bone uptake, grade 3 = myocardial uptake greater than bone uptake.
Qualitative data are number and percentage; continuous data are mean and SD or median and interquartile range.